文献速递神经介入CTDSA

REVASCAT随机对照试验中治疗后梗死体积与24小时及90天临床结局的比较

Posttreatment Infarct Volumes when Compared with 24-Hour and 90-Day Clinical Outcomes: Insights from the REVASCAT Randomized Controlled Trial.
PubMed 文献 · AJNR Am J Neuroradiol · 2017-11-23

REVASCAT多中心随机开放标签盲法评估试验纳入206例前循环颅内近端血栓所致缺血性卒中患者,比较血管内治疗与对照组的治疗后梗死体积,并分析其与24小时NIHSS评分和90天mRS的关系。结果显示血管内治疗组梗死体积中位数16.3 mL低于对照组38.6 mL(P=0.02),但24小时NIHSS评分强介导治疗类型与90天mRS的关系,而梗死体积未显示此介导作用。

要点

  • 血管内治疗组治疗后梗死体积中位数16.3 mL,对照组38.6 mL,组间差异P=0.02。
  • 基线NIHSS、闭塞部位、基线NCCT ASPECTS和再通状态独立相关于治疗后梗死体积。
  • 24小时NIHSS评分强介导治疗类型与90天mRS关系,梗死体积未显示介导作用(P=0.26)。

核心结论

  • 血管内治疗主要通过改善24小时卒中严重程度来挽救脑组织并改善90天临床结局。

研究设计与样本

  • REVASCAT为多中心随机开放标签试验,盲法评估结局;共纳入206例(血管内治疗组103例,对照组103例),其中204例测量了治疗后梗死体积;比较治疗后梗死体积与治疗分组及再通状态,采用统计模型评估基线临床和影像变量、治疗后梗死体积、24小时NIHSS评分与90天mRS的关系。

诊断标准与关键数值

  • 所有受试者治疗后梗死体积中位数为23.7 mL(四分位距68.9 mL)。
  • 血管内治疗组治疗后梗死体积中位数16.3 mL(四分位距50.2 mL),对照组38.6 mL(四分位距74.9 mL),组间比较P=0.02。
  • 基线NIHSS(P<0.01)、闭塞部位(P<0.03)、基线NCCT ASPECTS(P<0.01)和再通状态(P=0.02)独立相关于治疗后梗死体积。
  • 基线NIHSS(P<0.01)、症状发作至随机化时间(P=0.02)、治疗类型(P=0.04)和再通状态(P<0.01)独立相关于24小时NIHSS评分。
  • 24小时NIHSS评分强介导治疗类型与90天mRS的关系(校正年龄后间接效应P<0.01),治疗后梗死体积未显示介导作用(P=0.26)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND AND PURPOSE: Endovascular therapy has become the standard of care for patients with disabling anterior circulation ischemic stroke due to proximal intracranial thrombi. Our aim was to determine whether the beneficial effect of endovascular treatment on functional outcome could be explained by a reduction in posttreatment infarct volume in the Endovascular Revascularization With Solitaire Device Versus Best Medical Therapy in Anterior Circulation Stroke Within 8 Hours (REVASCAT) trial.

MATERIALS AND METHODS: The REVASCAT trial was a multicenter randomized open-label trial with blinded outcome evaluation. Among 206 enrolled subjects (endovascular treatment, n = 103; control, n = 103), posttreatment infarct volume was measured in 204 subjects. Posttreatment infarct volumes were compared with treatment assignment and recanalization status. Appropriate statistical models were used to assess the relationship among baseline clinical and imaging variables, posttreatment infarct volume, the 24-hour NIHSS score, and functional status with the 90-day modified Rankin Scale score.

RESULTS: The median posttreatment infarct volume in all subjects was 23.7 mL (interquartile range = 68.9 mL) and 16.3 mL (interquartile range = 50.2 mL) in the endovascular treatment arm and 38.6 mL (interquartile range = 74.9 mL) in the control arm (P = .02 for endovascular treatment versus control subjects). Baseline NIHSS (P < .01), site of occlusion (P < .03), baseline NCCT ASPECTS (P < .01), and recanalization status (P = .02) were independently associated with posttreatment infarct volume. Baseline NIHSS (P < .01), time from symptom onset to randomization (P = .02), treatment type (P = .04), and recanalization status (P < .01) were independently associated with the 24-hour NIHSS scores. The 24-hour NIHSS score strongly mediated the relationship between treatment type and 90-day mRS (P < .01 for indirect effect when adjusted for age), while posttreatment infarct volume did not (P = .26).

CONCLUSIONS: Endovascular treatment saves brain and improves 90-day clinical outcomes primarily through a beneficial effect on the 24-hour stroke severity.

来源:AJNR Am J Neuroradiol,查看原文。版权归原作者所有。

引用

  1. Al-Ajlan FS, Al Sultan AS, Minhas P, et al. Posttreatment Infarct Volumes when Compared with 24-Hour and 90-Day Clinical Outcomes: Insights from the REVASCAT Randomized Controlled Trial. AJNR Am J Neuroradiol. 2017. PMID: 29170266. doi:10.3174/ajnr.A5463

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。